Introduction: Transaminitis in psoriatic arthritis treated with disease modifying anti-rheumatic drugs (DMARDs) is common and significant liver damage is three times Health NHS more likely than in rheumatoid arthritis. Commonly described risk factors include non-alcoholic fatty liver disease, obesity, diabetes, alcohol, concomitant non-steroidal antiinflammatory drugs, corticosteroids and other DMARDs. Reactivation of hepatitis B virus (HBV) in patients undergoing immunosuppressive therapy is a well-recognized and potentially fatal complication, yet preventable. Here we report a rare case of HBV reactivation in a patient with psoriatic arthritis shortly after starting methotrexate treatment and to emphasize the importance of baseline screening for chronic HBV infection. Case description: A 30-year old Caucasian male patient was referred with longstanding psoriatic arthritis in May 2017. He had been treated with sulfasalazine in the past but has been without immunosuppression due to family planning since 2011. On examination he had active skin psoriasis and polyarthritis. There was no other significant past medical history, he was a non-smoker, consumed alcohol socially and did not use any illicit drugs. He had a long-term female sexual partner. His baseline blood tests including liver function tests were unremarkable. He was started on methotrexate 10 mg once weekly and folic acid 5 mg once weekly. On his two-week monitoring blood test his liver function tests were markedly deranged including alanine aminotransferase (ALT) of 2577 U/L and bilirubin 67 umol/L.He developed a transient period of jaundice lasted for one week but did not seek medical attention and continued with the methotrexate. He attended his follow-up rheumatology appointment four weeks after starting the methotrexate when he was no longer jaundiced and liver function test revealed improvement in his ALT at 119 U/L. Further liver investigations including a viral hepatitis screen revealed reactivation of HBV. His serology showed positive HBV surface antigen (HBsAg), low titre IgM core antibody, high titre IgG core antibody (anti-HBc), negative e antigen and positive e antibody, with an HBV DNA viral load of 2.11 log IU/ml. Discussion: There is a vast amount of evidence that HBV-induced liver inflammation is in fact mainly immune-mediated. HBV replication and expression of viral epitopes in infected hepatocytes is followed by a predominantlyCD8þT-lymphocyte induced acuteorchronic liver inflammation. In chronic HBV infection, spontaneous intermittent rises in ALT levels preceded by increase in serum HBV DNA are common. Immunosuppressive drugscan triggerthese flares, and inparticularcorticosteroids can directly stimulate HBV replication. Furthermore, the immunosuppressive effect on the host immune system indirectly leads to abundant viral replication. In addition, sudden withdrawal of immunosuppressive drugs can result in an exaggerated host immune response leading to potentially life-threatening liver injury. The list of immunosuppressive drugs associated with HBV reactivation has been constantly expanding. The most commonly reported synthetic DMARD associated with HBV reactivation is methotrexate. The risk of HBV reactivation by methotrexate alone is therefore considered to be low but higher with concomitant use of corticosteroids. Young male patients appear to be at highest risk of reactivation, although the risk mostly depends on HBsAg status. HBV screening standards and the prevention of HBV reactivation have dramatically changed in the past decade. Improved recommendations regarding screening for HBV infection prior to starting immunosuppressive agents or chemotherapy have been mastered by various gastroenterology societies. The latest one, for example, the 2017 clinical practice guideline by the European Association for the Study of
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